贝塔-1-上腺受体阻塞与雷诺现象风险之间的关联:孟德尔随机化研究
Jacob C Williams1,2, Kira Rogers3, Kathryn Coulson3
1St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Journal of scleroderma and related disorders
|March 31, 2025
概括
这项研究发现没有遗传证据将β-1-上腺受体阻塞与雷诺病联系起来.
科学领域:
- 药物遗传学 药物遗传学
- 心血管研究研究心血管研究
- 血管生物学 血管生物学
背景情况:
- 雷诺氏现象是一种影响生活质量的血管动性疾病.
- 贝塔-1-上腺受体阻断剂在雷诺病现象中的作用尚不清楚.
研究的目的:
- 调查基因模仿β-1-上腺受体阻塞与雷诺现象风险之间的关联.
- 用ADRB1基因中的遗传变异来评估因果关系.
主要方法:
- 利用英国生物库数据与个人级别信息.
- 在ADRB1基因中使用两个单核酸多态 (SNPs) 作为仪器变量.
- 使用ICD或Read代码定义雷诺现象,并分析了与血压生物标志物的关联.
主要成果:
- 在基因模仿的β-1-腺受体阻塞和雷诺现象风险之间没有发现显著的关联.
- 使用缩血压进行的分析显示OR为0.93 (95%CI [0.83,1.04],p=0.19).
- 使用透气血压进行的分析显示OR为0.91 (95%CI [0.78,1.05],p=0.19).
结论:
- 这项遗传研究没有发现贝塔-1-上腺受体阻塞和雷诺现象之间的因果关系的证据.
- 需要进行进一步的随机对照试验,以确认这些阻塞剂在雷诺现象患者中的安全性.
相关概念视频
Adrenergic Antagonists: ɑ and β-Receptor Blockers
393
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
393
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
504
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
504
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
475
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
475
Antihypertensive Drugs: Types of β-Blockers
521
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
521
Antihypertensive Drugs: Action of β1 Blockers
283
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
283
Adrenergic Receptors: β Subtype
1.4K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.4K


